Cost-Effectiveness of Preemptive Switching to Efavirenz-Based Antiretroviral Therapy for Children With Human Immunodeficiency Virus

BACKGROUND: The NEVEREST-3 (South Africa) and MONOD-ANRS-12206 (Côte d’Ivoire, Burkina Faso) randomized trials found that switching to efavirenz (EFV) in human immunodeficiency virus–infected children >3 years old who were virologically suppressed by ritonavir-boosted lopinavir (LPV/r) was noninf...

Descripción completa

Detalles Bibliográficos
Autores principales: Desmonde, Sophie, Frank, Simone C, Coovadia, Ashraf, Dahourou, Désiré L, Hou, Taige, Abrams, Elaine J, Amorissani-Folquet, Madeleine, Walensky, Rochelle P, Strehlau, Renate, Penazzato, Martina, Freedberg, Kenneth A, Kuhn, Louise, Leroy, Valeriane, Ciaranello, Andrea L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634435/
https://www.ncbi.nlm.nih.gov/pubmed/31334298
http://dx.doi.org/10.1093/ofid/ofz276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634435/
https://www.ncbi.nlm.nih.gov/pubmed/31334298
http://dx.doi.org/10.1093/ofid/ofz276

Ejemplares similares